KPIs & Operating Metrics(New)
Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesCurrent TaxesLiabilities and Shareholders EquityLong-Term InvestmentsNon-Current AssetsNon-Current Deffered RevenueOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Retained EarningsShareholder's EquityShort-term InvestmentsTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

CRISPR Therapeutics AG (CRSP) Other Non-Current Liabilities (2016 - 2025)

Historic Other Non-Current Liabilities for CRISPR Therapeutics AG (CRSP) over the last 11 years, with Q3 2025 value amounting to $5.3 million.

  • CRISPR Therapeutics AG's Other Non-Current Liabilities rose 4354.09% to $5.3 million in Q3 2025 from the same period last year, while for Sep 2025 it was $5.3 million, marking a year-over-year increase of 4354.09%. This contributed to the annual value of $3.4 million for FY2024, which is 25949.9% up from last year.
  • As of Q3 2025, CRISPR Therapeutics AG's Other Non-Current Liabilities stood at $5.3 million, which was up 4354.09% from $4.5 million recorded in Q2 2025.
  • In the past 5 years, CRISPR Therapeutics AG's Other Non-Current Liabilities ranged from a high of $8.7 million in Q2 2021 and a low of $958000.0 during Q4 2023
  • Its 5-year average for Other Non-Current Liabilities is $5.4 million, with a median of $5.4 million in 2023.
  • Its Other Non-Current Liabilities has fluctuated over the past 5 years, first plummeted by 8395.04% in 2023, then surged by 25949.9% in 2024.
  • Quarter analysis of 5 years shows CRISPR Therapeutics AG's Other Non-Current Liabilities stood at $7.3 million in 2021, then fell by 18.67% to $6.0 million in 2022, then crashed by 83.95% to $958000.0 in 2023, then skyrocketed by 259.5% to $3.4 million in 2024, then skyrocketed by 53.25% to $5.3 million in 2025.
  • Its Other Non-Current Liabilities stands at $5.3 million for Q3 2025, versus $4.5 million for Q2 2025 and $3.3 million for Q1 2025.